ES2618508T3 - Células que comprenden partículas lentivíricas con codones optimizados - Google Patents
Células que comprenden partículas lentivíricas con codones optimizados Download PDFInfo
- Publication number
- ES2618508T3 ES2618508T3 ES10158183.3T ES10158183T ES2618508T3 ES 2618508 T3 ES2618508 T3 ES 2618508T3 ES 10158183 T ES10158183 T ES 10158183T ES 2618508 T3 ES2618508 T3 ES 2618508T3
- Authority
- ES
- Spain
- Prior art keywords
- gag
- promoter
- gene
- cells
- shows
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OHKQZMWGUKSKRK-UHFFFAOYSA-N N=CCCCC[Th] Chemical compound N=CCCCC[Th] OHKQZMWGUKSKRK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Semiconductor Lasers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0009760.0A GB0009760D0 (en) | 2000-04-19 | 2000-04-19 | Method |
| GB0009760 | 2000-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2618508T3 true ES2618508T3 (es) | 2017-06-21 |
Family
ID=9890278
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10158183.3T Expired - Lifetime ES2618508T3 (es) | 2000-04-19 | 2001-04-18 | Células que comprenden partículas lentivíricas con codones optimizados |
| ES01921651T Expired - Lifetime ES2343564T3 (es) | 2000-04-19 | 2001-04-18 | Vectores de eiav con codones optimizados. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01921651T Expired - Lifetime ES2343564T3 (es) | 2000-04-19 | 2001-04-18 | Vectores de eiav con codones optimizados. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20050042234A1 (https=) |
| EP (2) | EP2194137B1 (https=) |
| JP (1) | JP4981231B2 (https=) |
| CN (2) | CN101024845B (https=) |
| AT (1) | ATE462796T1 (https=) |
| AU (1) | AU4861901A (https=) |
| CA (1) | CA2404129A1 (https=) |
| CY (1) | CY1110123T1 (https=) |
| DE (1) | DE60141690D1 (https=) |
| DK (2) | DK1278878T3 (https=) |
| ES (2) | ES2618508T3 (https=) |
| GB (1) | GB0009760D0 (https=) |
| PT (1) | PT1278878E (https=) |
| WO (1) | WO2001079518A2 (https=) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| US9738907B2 (en) | 2002-02-01 | 2017-08-22 | Oxford Biomedica (Uk) Limited | Viral vector |
| EP1504108B1 (en) * | 2002-02-01 | 2013-04-17 | Oxford Biomedica (UK) Limited | Lentiviral vector |
| JP2005533485A (ja) * | 2002-02-04 | 2005-11-10 | ノバルティス アクチエンゲゼルシャフト | 組換えウシ免疫不全ウイルスに基づく遺伝子導入システム |
| CN1980955A (zh) * | 2004-04-29 | 2007-06-13 | 北卡罗来纳-查佩尔山大学 | 增强细胞粘连特性的方法和组合物 |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| GB0526210D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Vectors |
| PL2307551T3 (pl) | 2008-06-18 | 2017-07-31 | Oxford Biomedica (Uk) Limited | Oczyszczanie wektorów retrowirusowych |
| CN102946907A (zh) | 2010-05-28 | 2013-02-27 | 牛津生物医学（英国）有限公司 | 慢病毒载体向脑的递送 |
| GB201118636D0 (en) | 2011-10-28 | 2011-12-07 | Oxford Biomedica Ltd | Nucleotide sequence |
| CA2909733C (en) | 2013-04-18 | 2023-10-17 | Fondazione Telethon | Effective delivery of large genes by dual aav vectors |
| ES2747951T3 (es) | 2013-10-24 | 2020-03-12 | Ospedale San Raffaele Srl | Método |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| SI3194434T1 (sl) | 2014-09-15 | 2019-11-29 | Molmed Spa | Himerni antigenski receptorji |
| GB201418965D0 (https=) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| US20190017096A1 (en) | 2016-03-10 | 2019-01-17 | Nightstarx Limited | Prenylation assay |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| EP3235828A1 (en) * | 2016-04-21 | 2017-10-25 | Genethon | Stable pseudotyped lentiviral particles and uses thereof |
| EP3318285A1 (en) | 2016-11-08 | 2018-05-09 | Oxford University Innovation Limited | Treatment of eye disease |
| WO2018099933A1 (en) | 2016-12-01 | 2018-06-07 | Nestec S.A. | Methods of modulating fam46a |
| CN108130333A (zh) * | 2016-12-01 | 2018-06-08 | 上海泽润生物科技有限公司 | 重组脊髓灰质炎ⅰ型病毒样颗粒 |
| EP3375876A1 (en) | 2017-03-13 | 2018-09-19 | Evonetix Ltd | Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures |
| CA3056542A1 (en) | 2017-03-15 | 2018-09-20 | Oxford Biomedica (Uk) Limited | Method |
| CN110475865A (zh) | 2017-03-31 | 2019-11-19 | 雀巢产品有限公司 | 调节ank1的方法 |
| GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| PT3612624T (pt) | 2017-04-21 | 2024-11-29 | Ospedale San Raffaele Srl | Terapia génica |
| WO2018197492A1 (en) | 2017-04-24 | 2018-11-01 | Ospedale San Raffaele S.R.L. | Tcr and peptides |
| WO2019068854A1 (en) | 2017-10-06 | 2019-04-11 | Ospedale San Raffaele S.R.L. | GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS |
| JP2021502820A (ja) | 2017-10-17 | 2021-02-04 | ナイトスタアールエックス リミテッド | プレニル化アッセイ |
| JP7477448B2 (ja) | 2017-11-21 | 2024-05-01 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Ａｌｋを調節する方法 |
| GB201720948D0 (en) * | 2017-12-15 | 2018-01-31 | Autolus Ltd | Plasmid system |
| EP3633040B1 (en) | 2017-12-22 | 2023-06-07 | Oxford BioMedica (UK) Limited | Retroviral vector |
| WO2019134866A1 (en) | 2018-01-03 | 2019-07-11 | Molmed Spa | Chimeric antigen receptors containing optimal spacer region |
| AU2019254824B2 (en) | 2018-04-18 | 2025-04-24 | Ucl Business Ltd | Method for enhancing the suppressive properties of Treg cells |
| AU2019269593A1 (en) | 2018-05-15 | 2020-11-26 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| WO2019219308A1 (en) | 2018-05-17 | 2019-11-21 | Societe Des Produits Nestle S.A. | Methods of modulating nkx6.3 |
| JP2021525066A (ja) | 2018-05-30 | 2021-09-24 | グリコステム セラピューティクス ベスローテン フェンノートシャップ | Ｃａｒ ｎｋ細胞 |
| EP3820509A1 (en) | 2018-07-09 | 2021-05-19 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| GB201817821D0 (en) | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| EP3880832A1 (en) | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| SG11202105079QA (en) | 2018-11-14 | 2021-06-29 | Flagship Pioneering Innovations V Inc | Fusosome compositions for cns delivery |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| GB201900687D0 (en) | 2019-01-17 | 2019-03-06 | King S College London | Immunotherapeutic methods and compositions |
| WO2020128478A1 (en) | 2018-12-19 | 2020-06-25 | King's College London | Immunotherapeutic methods and compositions |
| GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| US20220175962A1 (en) | 2019-03-10 | 2022-06-09 | Sio Gene Therapies Inc. | Gene therapy compositions and methods for treating parkinson's disease |
| GB201905301D0 (en) | 2019-04-15 | 2019-05-29 | Ospedale San Raffaele Srl | Gene therapy |
| GB201907493D0 (en) | 2019-05-28 | 2019-07-10 | Ospedale San Raffaele | Agents and methods for treating viral infections |
| GB201912515D0 (en) | 2019-08-30 | 2019-10-16 | King S College London | Engineered regulatory T cell |
| AU2020341454A1 (en) | 2019-09-03 | 2022-03-10 | Sana Biotechnology, Inc. | CD24-associated particles and related methods and uses thereof |
| WO2021094752A1 (en) | 2019-11-12 | 2021-05-20 | Oxford Biomedica (Uk) Limited | Production system |
| JP2023513303A (ja) | 2020-02-13 | 2023-03-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | レンチウイルスベクターの製造 |
| CN115427440A (zh) | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| US20230118587A1 (en) | 2020-03-13 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Lentiviral Vectors |
| JP2023521663A (ja) | 2020-03-31 | 2023-05-25 | サナ バイオテクノロジー，インコーポレイテッド | 標的化脂質粒子及び組成物ならびにその使用 |
| GB202007169D0 (en) | 2020-05-14 | 2020-07-01 | Ospedale San Raffaele Srl | Epidermal growth factor receptor |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| GB202013477D0 (en) | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| US20230303665A1 (en) | 2020-08-28 | 2023-09-28 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| GB202018657D0 (en) | 2020-11-26 | 2021-01-13 | Ospedale San Raffaele Srl | Agents and methods for increasing liver immune response |
| CN112430582B (zh) * | 2020-12-04 | 2022-05-03 | 北京艺妙神州医药科技有限公司 | 一种慢病毒稳定包装细胞系及其制备方法 |
| US20240052015A1 (en) | 2020-12-23 | 2024-02-15 | Quell Therapeutics Limited | Inducible signalling protein |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| KR20230152689A (ko) | 2021-02-01 | 2023-11-03 | 엡실렌 바이오 에스.알.엘. | 유전자 침묵 |
| KR20230171424A (ko) | 2021-02-15 | 2023-12-20 | 오스페달레 산 라파엘 에스.알.엘. | 암의 치료를 위한 후성적 침묵 |
| GB202102637D0 (en) | 2021-02-24 | 2021-04-07 | Quell Therapeutics Ltd | Engineered regulatory t cell |
| GB202102832D0 (en) * | 2021-02-26 | 2021-04-14 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| MX2023013393A (es) | 2021-05-12 | 2023-12-08 | Fond Telethon | Sistema de vectores. |
| AU2022280957A1 (en) | 2021-05-28 | 2023-11-30 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| TW202321286A (zh) | 2021-09-21 | 2023-06-01 | 英商圭爾醫療有限公司 | 抗p75ntr嵌合抗原受體 |
| WO2023047100A1 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-trem2 chimeric antigen receptor |
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| US20250230511A1 (en) | 2021-10-29 | 2025-07-17 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| EP4448775A1 (en) | 2021-12-17 | 2024-10-23 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| CN118434761A (zh) | 2021-12-22 | 2024-08-02 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| WO2023131657A1 (en) | 2022-01-05 | 2023-07-13 | Gyala Therapeutics Sociedad Limitada | Anti-cd84 antibodies and chimeric antigen receptors |
| EP4209511A1 (en) | 2022-01-05 | 2023-07-12 | Gyala Therapeutics Sociedad Limitada | Anti-cd84 antibodies amd chimeric antigen receptors |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| EP4269426A1 (en) | 2022-04-29 | 2023-11-01 | Ospedale San Raffaele S.r.l. | Gene therapy |
| EP4303226A1 (en) | 2022-07-08 | 2024-01-10 | Ospedale San Raffaele S.r.l. | Transgene cassettes and epigenetic silencers for the treatment of disorders |
| EP4551253A1 (en) | 2022-07-08 | 2025-05-14 | Ospedale San Raffaele S.r.l. | Transgene cassettes |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024033544A1 (en) | 2022-08-12 | 2024-02-15 | Ospedale San Raffaele S.R.L. | Deglycosylation of native glycoproteins expressed on a tumor cell surface |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4615492A1 (en) | 2022-11-08 | 2025-09-17 | Ospedale San Raffaele S.r.l. | Polynucleotide and vector |
| WO2024100294A1 (en) | 2022-11-11 | 2024-05-16 | Ospedale San Raffaele S.R.L. | Cdh17 car |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| WO2024153644A1 (en) | 2023-01-16 | 2024-07-25 | Ospedale San Raffaele S.R.L. | T-cell receptors |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| KR20250169635A (ko) | 2023-01-23 | 2025-12-03 | 메디치니쉐 호흐슐레 하노버 | 항-entpd3 키메라 항원 수용체 |
| IL322333A (en) | 2023-02-07 | 2025-09-01 | Quell Therapeutics Ltd | Culture method for TREG cells |
| EP4669343A1 (en) | 2023-02-24 | 2025-12-31 | Medizinische Hochschule Hannover | CHIMERIC ANTIGEN RECIPIENT |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194223A2 (en) | 2023-03-17 | 2024-09-26 | Ospedale San Raffaele S.R.L. | Gene therapy |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121586582A (zh) | 2023-03-20 | 2026-02-27 | 汉诺威医学院 | 嵌合抗原受体 |
| WO2024194642A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t regulatory cell |
| WO2024194649A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t cells and uses thereof |
| CN121219020A (zh) | 2023-03-22 | 2025-12-26 | 圣拉斐尔医院有限责任公司 | 基因疗法 |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| EP4698665A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| GB202307366D0 (en) | 2023-05-17 | 2023-06-28 | Ospedale San Raffaele Srl | Vector |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| EP4731648A1 (en) | 2023-06-21 | 2026-04-29 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| AU2024305679A1 (en) | 2023-06-28 | 2026-01-22 | Ospedale San Raffaele S.R.L. | T-cell receptors |
| WO2025032194A1 (en) | 2023-08-08 | 2025-02-13 | Ospedale San Raffaele S.R.L. | T-cell receptors |
| GB202316264D0 (en) | 2023-10-24 | 2023-12-06 | Ospendale San Raffaele S R L | Gene therapy |
| IT202300022191A1 (it) | 2023-10-24 | 2025-04-24 | Fond Telethon Ets | Mezzi e metodi per la modifica genetica di uba1 |
| WO2025109189A1 (en) | 2023-11-24 | 2025-05-30 | Ospedale San Raffaele S.R.L. | Engineered regulatory t cells and uses thereof |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| EP4640830A1 (en) | 2024-04-23 | 2025-10-29 | Fondazione Telethon ETS | Means and methods for safe and efficient gene editing in cells |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| WO2026027876A1 (en) | 2024-07-29 | 2026-02-05 | Quell Therapeutics Limited | Chimeric antigen receptor |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
| GB202415025D0 (en) | 2024-10-11 | 2024-11-27 | Ospedale San Raffaele Srl | Cell |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU611925B2 (en) | 1987-07-29 | 1991-06-27 | Basf Lacke & Farben Aktiengesellschaft | Aqueous electro-dipcoat baths containing cathodically depositable synthetic resins and process for coating electrically conductive substrates |
| WO1991000047A1 (en) | 1989-06-30 | 1991-01-10 | The Regents Of The University Of California | Retrovirus detection |
| EP1285967A3 (en) | 1990-09-21 | 2005-03-02 | Chiron Corporation | Human retroviral packaging cell line |
| US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
| AU3635695A (en) | 1994-09-19 | 1996-04-09 | Board Of Trustees Of The Leland Stanford Junior University | Methods for genetically modifying hematopoietic stem cells |
| US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| CA2237000A1 (en) | 1995-11-08 | 1997-05-15 | The Whitehead Institute For Biomedical Research | Stable packaging cell line producing pseudotyped retroviruses |
| US5739018A (en) | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
| US6133027A (en) | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| DE69729007T2 (de) | 1996-08-07 | 2005-04-07 | Darwin Discovery Ltd., Slough | Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| US6696291B2 (en) * | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
| JP4390860B2 (ja) * | 1997-05-13 | 2009-12-24 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | レンチウイルスをベースにした遺伝子転移ベクター |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| CN1303442A (zh) | 1997-09-23 | 2001-07-11 | 牛津生物医学（英国）有限公司 | 方法 |
| ES2373406T3 (es) * | 1997-12-22 | 2012-02-03 | Oxford Biomedica (Uk) Limited | Vectores basados en el virus de la anemia infecciosa equina (vaie). |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6958226B1 (en) * | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| AU6139699A (en) * | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
| WO2000039302A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| GB9906177D0 (en) * | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| PL351988A1 (en) * | 1999-04-26 | 2003-07-14 | Leuven K U Res & Dev | Synthetic gene for expressing active retroviral protein in eukaryotes |
| GB9923558D0 (en) * | 1999-10-05 | 1999-12-08 | Oxford Biomedica Ltd | Producer cell |
-
2000
- 2000-04-19 GB GBGB0009760.0A patent/GB0009760D0/en not_active Ceased
-
2001
- 2001-04-18 CN CN200610067908XA patent/CN101024845B/zh not_active Expired - Lifetime
- 2001-04-18 CA CA002404129A patent/CA2404129A1/en not_active Abandoned
- 2001-04-18 EP EP10158183.3A patent/EP2194137B1/en not_active Expired - Lifetime
- 2001-04-18 JP JP2001577501A patent/JP4981231B2/ja not_active Expired - Lifetime
- 2001-04-18 DE DE60141690T patent/DE60141690D1/de not_active Expired - Lifetime
- 2001-04-18 AT AT01921651T patent/ATE462796T1/de active
- 2001-04-18 CN CNB018084044A patent/CN1254543C/zh not_active Expired - Lifetime
- 2001-04-18 US US10/258,089 patent/US20050042234A1/en not_active Abandoned
- 2001-04-18 ES ES10158183.3T patent/ES2618508T3/es not_active Expired - Lifetime
- 2001-04-18 AU AU4861901A patent/AU4861901A/xx active Pending
- 2001-04-18 PT PT01921651T patent/PT1278878E/pt unknown
- 2001-04-18 EP EP01921651A patent/EP1278878B1/en not_active Expired - Lifetime
- 2001-04-18 DK DK01921651.4T patent/DK1278878T3/da active
- 2001-04-18 ES ES01921651T patent/ES2343564T3/es not_active Expired - Lifetime
- 2001-04-18 WO PCT/GB2001/001784 patent/WO2001079518A2/en not_active Ceased
- 2001-04-18 DK DK10158183.3T patent/DK2194137T3/en active
-
2008
- 2008-03-20 US US12/077,802 patent/US20080269473A1/en not_active Abandoned
-
2009
- 2009-10-02 US US12/587,236 patent/US20100273996A1/en not_active Abandoned
-
2010
- 2010-06-11 CY CY20101100538T patent/CY1110123T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101024845B (zh) | 2013-01-16 |
| AU2001248619B2 (en) | 2006-06-15 |
| CY1110123T1 (el) | 2015-01-14 |
| PT1278878E (pt) | 2010-05-31 |
| ATE462796T1 (de) | 2010-04-15 |
| EP2194137B1 (en) | 2016-12-21 |
| US20050042234A1 (en) | 2005-02-24 |
| DE60141690D1 (de) | 2010-05-12 |
| EP2194137A2 (en) | 2010-06-09 |
| DK1278878T3 (da) | 2010-06-28 |
| WO2001079518A2 (en) | 2001-10-25 |
| CN101024845A (zh) | 2007-08-29 |
| EP2194137A3 (en) | 2010-07-28 |
| EP1278878A2 (en) | 2003-01-29 |
| GB0009760D0 (en) | 2000-06-07 |
| JP4981231B2 (ja) | 2012-07-18 |
| WO2001079518A3 (en) | 2002-05-16 |
| AU4861901A (en) | 2001-10-30 |
| DK2194137T3 (en) | 2017-03-20 |
| CA2404129A1 (en) | 2001-10-25 |
| CN1426477A (zh) | 2003-06-25 |
| CN1254543C (zh) | 2006-05-03 |
| ES2343564T3 (es) | 2010-08-04 |
| EP1278878B1 (en) | 2010-03-31 |
| JP2004508808A (ja) | 2004-03-25 |
| US20100273996A1 (en) | 2010-10-28 |
| US20080269473A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2618508T3 (es) | Células que comprenden partículas lentivíricas con codones optimizados | |
| ES2298745T3 (es) | Promotores bidireccionales de sintesis y utilizacion de los mismos. | |
| EP0454781B1 (en) | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof | |
| JP4418536B2 (ja) | レトロウイルスベクター | |
| ES2634424T3 (es) | Vector multicistrónico lentivírico | |
| CN107523581B (zh) | 构建体 | |
| JP2001502903A (ja) | レンチウィルスベクター | |
| ES2744448T5 (es) | Vectores para la expresión transgénica | |
| US20150216948A1 (en) | Cytochrome p450 suicide gene system | |
| US6111087A (en) | Expression of a foamy virus envelope protein | |
| EP1706153A1 (en) | Minimal lentiviral vector system | |
| ES2329648T3 (es) | Clones moleculares con genes mutados gag/pol de vih, gag de vis y env de vis. | |
| US20020042136A1 (en) | Retroviral vectors comprising an enhanced 3' transcription termination structure | |
| Cannon et al. | Retroviral vectors for gene therapy | |
| Metharom et al. | Development of disabled, replication-defective gene transfer vectors from the Jembrana disease virus, a new infectious agent of cattle | |
| JP2022525136A (ja) | パーキンソン病を処置するための遺伝子治療組成物および方法 | |
| ES2236888T3 (es) | Expresion de una proteina modificada de la envoltura del virus espumoso. | |
| Binder et al. | Lentivirus vectors | |
| HK1034283B (en) | Use of triplex structure dna sequences for transferring nucleotide sequences | |
| HK1034283A1 (en) | Use of triplex structure dna sequences for transferring nucleotide sequences | |
| Meager | Gene Transfer Vectors for Clinical Applications | |
| Goodrich | Construction of a novel self-inactivating gene activating vector: Splicing and non-encapsidation of vector RNA | |
| HK1149289A (en) | Use of lentiviral triplex forming sequences for nuclear transfer of nucleotide sequences | |
| CA2376790A1 (en) | Siv-based packaging-defficient vectors |